Mediclinic

mediclinic.com

Mediclinic Southern Africa is a private hospital group operating in South Africa and Namibia focused on providing acute care, specialist-orientated, multi-disciplinary hospital services and related service offerings. Mediclinic Southern Africa places science at the heart of its care process by striving to provide evidence-based care of the highest standard. Mediclinic Southern Africa currently operates 48 private hospitals and three day clinics throughout South Africa and three hospitals in Namibia with more than 8 100 beds in total.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INOVIO PHARMACEUTICALS KICKS OFF PHASE 1 CLINICAL TRIAL FOR EXPERIMENTAL COVID-19 VACCINE

The Motley Fool | April 06, 2020

news image

Inovio Pharmaceuticals (NASDAQ:INO) has been moving fast in the race to develop a vaccine for COVID-19. The company claimed it had created a potential vaccine for the rapidly spreading coronavirus on Jan. 10, just three hours after Chinese researchers publicly released the genetic sequence of SARS-CoV-2 the virus that causes the illness. Now, it's starting human clinical trials for that potential vaccine, INO-4800. The trial will involve up to 40 healthy adult volunteers, each of whom ...

Read More

Business Insights

NOVO NORDISK TO ACQUIRE FORMA THERAPEUTICS AND EXPAND PRESENCE IN SICKLE CELL DISEASE AND RARE BLOOD DISORDERS

Novo Nordisk | September 02, 2022

news image

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead developm...

Read More

Business Insights, PHARMA TECH

MTTI RECEIVES CHINESE PATENT FOR EVATHERA TECHNOLOGY

Molecular Targeting Technologies, Inc. | December 07, 2022

news image

Molecular Targeting Technologies, Inc. announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform. Approval of “Chemical conjugates of Evans blue derivatives and their use as radiotherapeutic and imaging agents” follows issued patents in the US, Europe, Singapore, and Japan this past year. EBTATE is a new generation of peptide receptor radiotherapeutic drug that has...

Read More

Business Insights

INDIVIOR TO ACQUIRE OPIANT PHARMACEUTICALS

Indivior | November 21, 2022

news image

Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch. The transaction has been unanimously approved by the boards of di...

Read More
news image

INOVIO PHARMACEUTICALS KICKS OFF PHASE 1 CLINICAL TRIAL FOR EXPERIMENTAL COVID-19 VACCINE

The Motley Fool | April 06, 2020

Inovio Pharmaceuticals (NASDAQ:INO) has been moving fast in the race to develop a vaccine for COVID-19. The company claimed it had created a potential vaccine for the rapidly spreading coronavirus on Jan. 10, just three hours after Chinese researchers publicly released the genetic sequence of SARS-CoV-2 the virus that causes the illness. Now, it's starting human clinical trials for that potential vaccine, INO-4800. The trial will involve up to 40 healthy adult volunteers, each of whom ...

Read More
news image

Business Insights

NOVO NORDISK TO ACQUIRE FORMA THERAPEUTICS AND EXPAND PRESENCE IN SICKLE CELL DISEASE AND RARE BLOOD DISORDERS

Novo Nordisk | September 02, 2022

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead developm...

Read More
news image

Business Insights, PHARMA TECH

MTTI RECEIVES CHINESE PATENT FOR EVATHERA TECHNOLOGY

Molecular Targeting Technologies, Inc. | December 07, 2022

Molecular Targeting Technologies, Inc. announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform. Approval of “Chemical conjugates of Evans blue derivatives and their use as radiotherapeutic and imaging agents” follows issued patents in the US, Europe, Singapore, and Japan this past year. EBTATE is a new generation of peptide receptor radiotherapeutic drug that has...

Read More
news image

Business Insights

INDIVIOR TO ACQUIRE OPIANT PHARMACEUTICALS

Indivior | November 21, 2022

Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch. The transaction has been unanimously approved by the boards of di...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us